552331-57-4

Usage

Uses

Used in Organic Synthesis:
Pyridine, 4-ethenyl-2-fluoro(9CI) is used as a key intermediate in organic synthesis for the production of various chemical compounds. Its unique structure allows for selective functionalization and modification, enabling the synthesis of a wide range of molecules with diverse properties and applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Pyridine, 4-ethenyl-2-fluoro(9CI) is utilized as a reagent and building block in the development of new drugs. Its presence in the molecular structure can impart specific biological activities, making it a valuable component in the design and synthesis of pharmaceutical agents.
Used in Agrochemical Industry:
Pyridine, 4-ethenyl-2-fluoro(9CI) also finds applications in the agrochemical industry, where it is used as a precursor in the synthesis of agrochemicals such as pesticides and herbicides. Its unique properties can contribute to the effectiveness and selectivity of these agrochemicals.
Used in Materials Science:
In the field of materials science, Pyridine, 4-ethenyl-2-fluoro(9CI) has potential applications in the development of new materials with specific properties. Its incorporation into polymers, coatings, or other materials can enhance their performance or introduce new functionalities.
Used in Nanotechnology:
Pyridine, 4-ethenyl-2-fluoro(9CI) can also be employed in nanotechnology for the synthesis of nanomaterials with unique properties. Its presence in the molecular structure of these materials can influence their size, shape, and surface properties, making them suitable for various applications in electronics, medicine, and other fields.

Upstream product

• 7486-35-3 tri-n-butyl(vinyl)tin 
• 22282-70-8 2-fluoro-4-iodopyridine 
• 1176209-54-3 2-(2-fluoropyridin-4-yl)ethyl methylsulfonate 
• 697216-36-7 N₁-ethyl-N₂-phthalyl-1,2-ethanediamine 
• 128071-98-7 4-bromo-2-fluoropyridine 
• 75927-49-0 pinacol vinylboronate 
• 1000562-43-5 2-fluoro-4-(2-hydroxyethyl)pyridine 
• 461-87-0 2-fluoro-4-methylpyridine 
• 372-48-5 2-fluoropyridine 

Downstream Products

• 1430235-19-0 C₁₉H₁₈FNSi 
• 1430235-43-0 C₁₉H₁₆FNSi 
• 882170-48-1 [1-{5-[2-(2-benzylamino-pyridin-4-yl)-vinyl]-pyridin-3-yloxymethyl}-2-(1H-indol-3-yl)-ethyl]-carbamic acid tert-butyl ester 
• 882170-43-6 [1-{5-[2-(2-benzylsulfanyl-pyridin-4-yl)-vinyl]-pyridin-3-yloxymethyl}-2-(1H-indol-3-yl)-ethyl]-carbamic acid tert-butyl ester 
• 882170-42-5 (2-(1H-indol-3-yl)-1-{5-[2-(2-phenylsulfanyl-pyridin-4-yl)-vinyl]-pyridin-3-yloxymethyl}-ethyl)-carbamic acid tert-butyl ester 
• 882170-41-4 (2-(1H-indol-3-yl)-1-{5-[2-(2-phenoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxymethyl}-ethyl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Fe-Catalyzed Reductive Couplings of Terminal (Hetero)Aryl Alkenes and Alkyl Halides under Aqueous Micellar Conditions

The combination of a vinyl-substituted aromatic or heteroaromatic and an alkyl bromide or iodide leads, in the presence of Zn and a catalytic amount of an Fe(II) salt, to a net reductive coupling. The new C-C bond is regiospecifically formed at rt at the β-site of the alkene. The coupling only occurs in an aqueous micellar medium, where a radical process is likely, supported by several control experiments. A mechanism based on these data is proposed.

Single photon emission computed tomography/positron emission tomography imaging and targeted radionuclide therapy of melanoma: New multimodal fluorinated and iodinated radiotracers

This study reports a series of 14 new iodinated and fluorinated compounds offering both early imaging (123I, 124I, 18F) and systemic treatment (131I) of melanoma potentialities. The biodistribution of each 125I-labeled tracer was evaluated in a model of melanoma B16F0-bearing mice, using in vivo serial γ scintigraphic imaging. Among this series, [125I]56 emerged as the most promising compound in terms of specific tumoral uptake and in vivo kinetic profile. To validate our multimodality concept, the radiosynthesis of [18F]56 was then optimized and this radiotracer has been successfully investigated for in vivo PET imaging of melanoma in B16F0- and B16F10-bearing mouse model. The therapeutic efficacy of [131I]56 was then evaluated in mice bearing subcutaneous B16F0 melanoma, and a significant slow down in tumoral growth was demonstrated. These data support further development of 56 for PET imaging (18F, 124I) and targeted radionuclide therapy ( 131I) of melanoma using a single chemical structure.

Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors

The present invention relates to the compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen atom, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group

Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation

A novel series of Akt/PKB inhibitors derived from a screening lead (1) has been prepared. The novel trans-3,4′-bispyridinylethylenes described herein are potent inhibitors of Akt/PKB with IC50 values in the low double-digit nanomolar range against Akt1. Compound 2q shows excellent selectivity against distinct families of kinases such as tyrosine kinases and CAMK, and displays poor to modest selectivity against closely related kinases in the AGC and CMGC families. The cellular activities including inhibition of cell growth and phosphorylation of downstream target GSK3 are also described. The X-ray structure of compound 2q complexed with PKA in the ATP binding site was determined.

5-Substituted Derivatives of 6-Halogeno-3-((2-(S)-azetidinyl)methoxy)pyridine and 6-Halogeno-3-((2-(S)-pyrrolidinyl)methoxy)pyridine with Low Picomolar Affinity for α4β2 Nicotinic Acetylcholine Receptor and Wide Range of Lipophilicity: Potential Probes for Imaging with Positron Emission Tomography

Potential positron emission tomography (PET) ligands with low picomolar affinity at the nicotinic acetylcholine receptor (nAChR) and with lipophilicity (log D) ranging from - 1.6 to +1.5 have been synthesized. Most members of the series, which are derivatives of 5-substituted-6-halogeno-A-85380, exhibited a higher binding affinity at α4β2-nAChRs than epibatidine. An analysis, by molecular modeling, revealed an important role of the orientation of the additional heterocyclic ring on the binding affinity of the ligands with nAChRs. The existing nicotinic pharmacophore models do not accommodate this finding. Two compounds of the series, 6-[18F]fluoro-5-(pyridin-3-yl)-A-85380 ([18F]31) and 6-chloro-3-((2-(S)-azetidinyl)methoxy)-5-(2-[ 18F]fluoropyridin-5-yl)pyridine) ([18F]35), were radiolabeled with 18F. Comparison of PET data for [18F]31 and 2-[18F]FA shows the influence of lipophilicity on the binding potential. Our recent PET studies with [18F]35 demonstrated that its binding potential values in Rhesus monkey brain were ca. 2.5 times those of 2-[18F]FA. Therefore, [18F]35 and several other members of the series, when radiolabeled, will be suitable for quantitative imaging of extrathalamic nAChRs.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.